Komori
General Meetings of Shareholders4882Perseus Proteomics Inc.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials

The 26th Annual General Meeting of Shareholders will be held on 24 June 2026, with proposals submitted for amendment of the Articles of Incorporation and the election of directors and other officers. The proposed amendments include expanding the business purposes, increasing the total number of authorized shares from 24,000,000 to 50,000,000, and introducing virtual-only shareholders meetings.

Worth reading
57In focus
Scored from 3 of 4 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
26000000
Shares (increase in the total number of authorized shares)
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual, 26th
2026
Jun 24
Date and time(registration opens at 9:30 a.m.)21 days from this disclosure to the meeting
Matters for resolution4 items
  1. Partial amendments to the Articles of Incorporation

  2. Election of 5 directors, excluding directors who are Audit and Supervisory Committee Members

  3. Election of 2 directors who are Audit and Supervisory Committee Members

  4. Election of 1 Substitute Director who is an Audit and Supervisory Committee Member

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee8 candidates. Of these, 3 are new candidates and 5 are outside candidates. The breakdown is 5 directors who are not Audit and Supervisory Committee Members, 2 directors who are Audit and Supervisory Committee Members, and 1 alternate director who is an Audit and Supervisory Committee Member.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual, 26th
Date and time10:00 a.m. on Wednesday, 24 June 2026 (registration opens at 9:30 a.m.)
Matters for resolutionProposal No. 1: Partial amendments to the Articles of Incorporation, Proposal No. 2: Election of 5 directors, excluding directors who are Audit and Supervisory Committee Members, Proposal No. 3: Election of 2 directors who are Audit and Supervisory Committee Members, Proposal No. 4: Election of 1 Substitute Director who is an Audit and Supervisory Committee Member
Shareholder ProposalNo
Director nominee8 candidates. Of these, 3 are new candidates and 5 are outside candidates. The breakdown is 5 directors who are not Audit and Supervisory Committee Members, 2 directors who are Audit and Supervisory Committee Members, and 1 alternate director who is an Audit and Supervisory Committee Member.
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To accommodate the expansion and diversification of business areas; enable flexible capital policies; clarify the terms of office of additional and alternate directors; establish a system capable of conducting effective audits even when no full-time Audit and Supervisory Committee Member is appointed; reduce the risk of holding a meeting being affected by infectious diseases, natural disasters and other events; expand opportunities for shareholders in remote locations to attend; revitalize and improve the efficiency of shareholders meetings; and pursue flexible capital and dividend policies.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials | Perseus Proteomics Inc. (4882) timely disclosure | Komori